Nektar Therapeutics (NKTR)

Nektar Therapeutics' stock (NKTR) has experienced significant activity, with a substantial increase of 524.35% between March 27, 2025, and March 26, 2026, and a 518.56% increase over the last 12 months. Key events impacting the stock include positive Phase 2b results for rezpegaldesleukin in atopic dermatitis and alopecia areata, a public offering that raised $460 million, presentations at conferences, Q4 2025 financial results indicating a decrease in revenue, analyst coverage, and a securities class action lawsuit alleging overstated trial integrity prospects.

Nektar Therapeutics' common stock exhibits some demand seasonality based on 27 years of historical data, with a "Poor" consistency score of 32.3. November has been the strongest month, with an average return of 7.92%, while May tends to be the weakest month, with an average return of -2.52%. The average annual return for NKTR is 14.38%.

Nektar Therapeutics is an American biopharmaceutical company focused on discovering and developing novel therapies for immune-mediated diseases, including autoimmune disorders, chronic inflammatory conditions, and cancer. The company leverages its proprietary PEGylation and advanced polymer conjugate technologies to enhance drug characteristics and its T-cell modulatory therapies to harness the body's immune system. Key drug candidates include Rezpegaldesleukin (REZPEG, NKTR-358), NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255. Nektar also developed Exubera and Movantik and previously had etirinotecan pegol licensed to a global partner.

Nektar Therapeutics is headquartered in San Francisco, California, U.S. The company conducts its research and development activities primarily within the United States and collaborates with international pharmaceutical companies.

Nektar Therapeutics' brand reputation has been influenced by positive clinical developments and a legal challenge. Positive Phase 2b clinical trial results for rezpegaldesleukin and FDA Fast Track designations contribute to a reputation of scientific innovation. However, a securities class action lawsuit alleging overstated trial integrity has created scrutiny and could negatively impact investor confidence.

Nektar Therapeutics' stock ownership is a mix of institutional, retail, and individual investors. Institutions hold a significant portion, with approximately 68% ownership as of February 11, 2026. Major institutional owners include BVF Inc/il, Vanguard Group Inc, and BlackRock, Inc. Individual insiders own less than 1% of the company, while the general public holds approximately a 25% stake. Deep Track Capital LP is the largest individual shareholder, owning 63.94% of the company.